In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.
作者信息
Kitzis M D, Ly A, Goldstein F W
出版信息
Antimicrob Agents Chemother. 2004 Jan;48(1):366-7. doi: 10.1128/AAC.48.1.366-367.2004.
Abstract
摘要
相似文献
1
In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.替加环素（GAR-936）对多重耐药金黄色葡萄球菌和肺炎链球菌的体外活性。
Antimicrob Agents Chemother. 2004 Jan;48(1):366-7. doi: 10.1128/AAC.48.1.366-367.2004.
2
In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.GAR-936对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的体外活性。
Diagn Microbiol Infect Dis. 2000 Nov;38(3):177-9. doi: 10.1016/s0732-8893(00)00193-0.
3
In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.替加环素对喹诺酮耐药肺炎链球菌、耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌的体外活性。
Int J Antimicrob Agents. 2007 Feb;29(2):191-6. doi: 10.1016/j.ijantimicag.2006.08.048. Epub 2006 Dec 13.
4
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).新型甘氨酰环素（米诺环素的9-叔丁基甘氨酰胺衍生物，GAR-936）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
5
Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline.四环素耐药决定因素的存在以及对替加环素和米诺环素的敏感性。
Antimicrob Agents Chemother. 2005 Apr;49(4):1636-8. doi: 10.1128/AAC.49.4.1636-1638.2005.
6
Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.替加环素对肺炎链球菌和金黄色葡萄球菌临床分离株的突变预防浓度。
J Antimicrob Chemother. 2015 Feb;70(2):494-7. doi: 10.1093/jac/dku389. Epub 2014 Oct 16.
7
Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.新型甘氨酰环素衍生物的合成及其构效关系与GAR-936的发现
Bioorg Med Chem Lett. 1999 May 17;9(10):1459-62. doi: 10.1016/s0960-894x(99)00216-4.
8
Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.替加环素对亚洲国家近期呼吸道病原体分离株的抗菌活性。
Diagn Microbiol Infect Dis. 2006 Aug;55(4):337-41. doi: 10.1016/j.diagmicrobio.2006.02.001. Epub 2006 May 2.
9
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.新型甘氨酰环素GAR-936对1203株近期临床分离细菌的抗菌活性及抗菌谱
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
10
Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus.
Int J Antimicrob Agents. 2002 Sep;20(3):220-2. doi: 10.1016/s0924-8579(02)00132-2.
引用本文的文献
1
Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.新型甘氨酰环素类化合物替加环素在新鲜制备培养基及质量控制中的体外抗菌活性比较
J Clin Microbiol. 2007 Jul;45(7):2173-9. doi: 10.1128/JCM.02351-06. Epub 2007 May 9.
2
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.波兰四环素不敏感肺炎链球菌分离株的克隆多样性及耐药机制
Antimicrob Agents Chemother. 2007 Apr;51(4):1155-63. doi: 10.1128/AAC.01384-06. Epub 2007 Jan 8.
3
Antibiotics for treatment of resistant gram-positive coccal infections.用于治疗耐革兰氏阳性球菌感染的抗生素。
Indian J Pediatr. 2006 Apr;73(4):323-34. doi: 10.1007/BF02825827.
4
Gram-positive cocci infections in intensive care: guide to antibacterial selection.重症监护中的革兰氏阳性球菌感染：抗菌药物选择指南
Drugs. 2006;66(6):751-68. doi: 10.2165/00003495-200666060-00003.
5
Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.1991年至2003年台湾某大学医院耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌引起的医院感染：耐药趋势、抗生素使用情况及新型抗菌药物的体外活性
Int J Antimicrob Agents. 2005 Jul;26(1):43-9. doi: 10.1016/j.ijantimicag.2005.04.007.
本文引用的文献
1
[Staphylococci resistant to antibiotic therapy].[对抗生素治疗耐药的葡萄球菌]
Ann Fr Anesth Reanim. 2002 May;21(5):375-83. doi: 10.1016/s0750-7658(02)00622-6.
2
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.替加环素（GAR-936）对西班牙近期分离的临床细菌的体外活性。
Antimicrob Agents Chemother. 2002 Mar;46(3):892-5. doi: 10.1128/AAC.46.3.892-895.2002.
3
Glycylcyclines: third-generation tetracycline antibiotics.甘氨酰环素类：第三代四环素类抗生素。
Curr Opin Pharmacol. 2001 Oct;1(5):464-9. doi: 10.1016/s1471-4892(01)00081-9.
4
The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.欧洲抗生素耐药性不断演变的威胁：亚历山大项目的新数据
J Antimicrob Chemother. 2000 Jul;46 Suppl T1:3-9. doi: 10.1093/oxfordjournals.jac.a020891.
5
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.甘氨酰环素GAR-936对革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
6
Penicillin-resistant Streptococcus pneumoniae: selection by both beta-lactam and non-beta-lactam antibiotics.耐青霉素肺炎链球菌：由β-内酰胺类抗生素和非β-内酰胺类抗生素共同筛选产生。
J Antimicrob Chemother. 1999 Aug;44(2):141-4. doi: 10.1093/jac/44.2.141.
7
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).新型甘氨酰环素（米诺环素的9-叔丁基甘氨酰胺衍生物，GAR-936）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
8
Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌对替考拉宁的敏感性降低
J Infect Dis. 1995 Jun;171(6):1646-50. doi: 10.1093/infdis/171.6.1646.
Zotero 插件